LOS ANGELES, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the Company will hold a conference call to discuss the data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor's Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute. An abstract entitled "Heart-derived Cell Therapy for Duchenne Cardiomyopathy: Cardiosphere-derived Cells and their Exosomes Improve Function, Restore Mitochondrial Integrity and Reverse Degenerative Changes in the Hearts of Mdx Mice," will be presented at the Late Breaking Basic Science Posters and Reception at the American Heart Association's Scientific Sessions 2014.
On the call, Dr. Linda Marbán, Chief Executive Officer of Capricor and Dr. Eduardo Marbán will review the data findings and provide an update on Capricor's plans to pursue a clinical program using the Company's lead product candidate, CAP-1002 for the treatment of Duchenne Muscular Dystrophy.
Participants can dial in to the call at: (Please ask to be directed to the Capricor call)
|PARTICIPANT DIAL IN (TOLL FREE):||1-866-652-5200|
|PARTICIPANT INTERNATIONAL DIAL IN:||1-412-317-6060|
Participants may also listen online and view the slide presentation by clicking the following link: http://services.choruscall.com/links/capr141112.html.
For those unable to join the call a replay will be available one hour after the conclusion of the call. This call will be available for replay until February 18, 2015 by calling:
|US Toll Free:||1-877-344-7529|
|Canada Toll Free:||1-855-669-9658|
|Replay Access Code:||10056019|
About Capricor Therapeutics
Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on August 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.
CONTACT: For more information, please contact: Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 email@example.com ProActive Capital Group Kirin Smith, COO +1-646-863-6519 ksmith@ProActiveCapital.com www.ProActiveCapital.com